SG11201906414VA - Calicheamicin derivatives and antibody drug conjugates thereof - Google Patents

Calicheamicin derivatives and antibody drug conjugates thereof

Info

Publication number
SG11201906414VA
SG11201906414VA SG11201906414VA SG11201906414VA SG11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA SG 11201906414V A SG11201906414V A SG 11201906414VA
Authority
SG
Singapore
Prior art keywords
international
rule
connecticut
street
avenue
Prior art date
Application number
SG11201906414VA
Inventor
Omar Khaled Ahmad
Stephen Paul Brown
Kenneth John Dirico
Russell DUSHIN
Gary Frederick Filzen
Sujiet Puthenveetil
Pavel Strop
Chakrapani Subramanyam
Lawrence N Tumey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201906414VA publication Critical patent/SG11201906414VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WI P0 I P C T oil1 oil muoin Imo oimIE (10) International Publication Number WO 2018/138591 Al (51) International Patent Classification: C07H 15/00 (2006.01) A61K 47/64 (2017.01) (21) International Application Number: PCT/IB2018/050153 (22) International Filing Date: 10 January 2018 (10.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/449,839 24 January 2017 (24.01.2017) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). (72) Inventors: AHMAD, Omar Khaled; 200 Exchange Street, Unit 512, Providence, Rhode Island 02903 (US). BROWN, Stephen Paul; 19 Walter Fish Avenue, Mystic, Connecti- cut 06355 (US). DIRICO, Kenneth John; 8 Melanie Lane, Gales Ferry, Connecticut 06335 (US). DUSHIN, Russell; 15 Jericho Drive, Old Lyme, Connecticut 06371 (US). FILZEN, Gary Frederick; 125 Markley Road, Sch- wenksville, Pennsylvania 19473 (US). PUTHENVEETIL, Sujiet; 10 Catherine Avenue, Franklin, Massachusetts 02038 (US). STROP, Pavel; 461 West 25th Avenue, San Mateo, California 94403 (US). SUBRAMANYAM, Chakrapani; 314 Great Pond Road, South Glastonbury, Connecticut 06073 (US). TUMEY, Lawrence N.; 37 William Street, Pawcatuck, Connecticut 06379 (US). (74) Agent: WALDRON, Roy F.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 1-1 GC 1-1 1-1 0> (57) : The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates \" (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the 0 same and to methods for using the same to treat pathological conditions such as cancer. (54) Title: CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF
SG11201906414VA 2017-01-24 2018-01-10 Calicheamicin derivatives and antibody drug conjugates thereof SG11201906414VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449839P 2017-01-24 2017-01-24
PCT/IB2018/050153 WO2018138591A1 (en) 2017-01-24 2018-01-10 Calicheamicin derivatives and antibody drug conjugates thereof

Publications (1)

Publication Number Publication Date
SG11201906414VA true SG11201906414VA (en) 2019-08-27

Family

ID=61168135

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906414VA SG11201906414VA (en) 2017-01-24 2018-01-10 Calicheamicin derivatives and antibody drug conjugates thereof

Country Status (14)

Country Link
US (1) US11993625B2 (en)
EP (1) EP3573995A1 (en)
JP (1) JP7078405B2 (en)
KR (1) KR20190111086A (en)
CN (1) CN110461860A (en)
AU (1) AU2018211561B2 (en)
BR (1) BR112019015069A2 (en)
CA (1) CA3051038C (en)
IL (1) IL268245A (en)
MX (1) MX2019008773A (en)
RU (1) RU2732568C1 (en)
SG (1) SG11201906414VA (en)
TW (1) TWI687221B (en)
WO (1) WO2018138591A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110725A1 (en) 2017-12-06 2019-06-13 Synaffix B.V. Enediyne conjugates
WO2020245229A1 (en) * 2019-06-03 2020-12-10 Synaffix B.V. Acetal-based cleavable linkers
GB2585102B (en) 2019-10-09 2021-06-30 Audio Inventions Ltd System for identification of a note played by a musical instrument

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0313874B1 (en) 1987-10-30 1994-04-13 American Cyanamid Company Disulfur analogs of LL-E33288 antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
WO2005009882A1 (en) * 2003-06-27 2005-02-03 Otis Elevator Company Absolute positioning system for elevators using dual encoders
HUE057936T2 (en) 2005-07-18 2022-06-28 Seagen Inc Beta-glucuronide drug linker conjugates
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112012031727B1 (en) * 2010-06-15 2022-03-29 Genmab A/S DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION, AND, USE OF DRUG-ANTIBODY CONJUGATE
RU2012157167A (en) 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Polyfunctional antibody conjugates
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
KR101981873B1 (en) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6355641B2 (en) 2012-11-05 2018-07-11 ファイザー・インク Spiraisostatin analog
US9453508B2 (en) 2013-02-25 2016-09-27 Asmo Co., Ltd. Electric oil pump and hydraulic pressure supply device
KR101614151B1 (en) 2014-07-01 2016-04-22 한국화학연구원 Lung Model Apparatus for Testing Inhalation Toxicity of Nano Paticles
WO2016030791A1 (en) 2014-08-28 2016-03-03 Pfizer Inc. Stability-modulating linkers for use with antibody drug conjugates
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
WO2018069851A2 (en) 2016-10-11 2018-04-19 Sorrento Therapeutics, Inc. C-met antibody drug conjugate

Also Published As

Publication number Publication date
AU2018211561A1 (en) 2019-07-18
CN110461860A (en) 2019-11-15
US20190345186A1 (en) 2019-11-14
RU2732568C1 (en) 2020-09-21
IL268245A (en) 2019-09-26
CA3051038A1 (en) 2018-08-02
JP2018123122A (en) 2018-08-09
BR112019015069A2 (en) 2020-03-03
AU2018211561B2 (en) 2020-04-30
JP7078405B2 (en) 2022-05-31
CA3051038C (en) 2022-07-26
MX2019008773A (en) 2019-09-18
KR20190111086A (en) 2019-10-01
TW201838632A (en) 2018-11-01
US11993625B2 (en) 2024-05-28
TWI687221B (en) 2020-03-11
EP3573995A1 (en) 2019-12-04
WO2018138591A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201907034PA (en) Methods of treating influenza
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809301YA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201805375PA (en) Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer
SG11201906414VA (en) Calicheamicin derivatives and antibody drug conjugates thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201811161YA (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
SG11201902531QA (en) Liquid pharmaceutical composition